Product Details

SLU-PP-332 is a synthetic small-molecule compound classified as a pan-estrogen-related receptor (ERR) agonist. It is structurally designed to interact with nuclear receptor subtypes ERRα, ERRβ, and ERRγ, with a higher binding affinity observed toward ERRα in controlled research settings. This compound is utilized in laboratory environments to study receptor-mediated transcriptional activity and intracellular signaling associated with nuclear receptor pathways.

Mechanism of Action

SLU-PP-332 functions as an agonist of estrogen-related receptors (ERRs), which are orphan nuclear receptors involved in transcriptional regulation. Upon binding to ERRα, ERRβ, or ERRγ, the compound facilitates receptor activation, leading to conformational changes that promote the recruitment of coactivator proteins.

This receptor-coactivator interaction influences gene transcription processes associated with mitochondrial function and cellular energy regulation pathways. Additionally, ERR activation is linked to the modulation of genes involved in oxidative phosphorylation and metabolic enzyme expression at the molecular level.

The compound is studied in terms of its ability to regulate transcriptional networks, receptor binding affinity, and downstream signaling pathways within controlled experimental systems.

Chemical Properties of SLU-PP-332

Research Applications

• Estrogen-Related Receptor Activation Studies

SLU-PP-332 is used in research focused on ligand binding and activation of ERR subtypes. Studies examine receptor affinity, activation kinetics, and downstream transcriptional effects.

• Nuclear Receptor Transcriptional Regulation

The compound is investigated for its role in modulating gene transcription through nuclear receptor signaling. Research explores coactivator recruitment and receptor-mediated transcriptional control mechanisms.

• Mitochondrial Function Pathway Analysis

SLU-PP-332 is examined in studies analyzing pathways associated with mitochondrial regulation. These investigations focus on transcriptional networks linked to energy-related biochemical processes.

• Oxidative Phosphorylation Signaling

Research includes evaluation of how ERR activation influences genes associated with oxidative phosphorylation. Studies are centered on molecular signaling and enzyme regulation within cellular systems.

Why Choose BehemothLabz to Buy SLU-PP-332 for Research

BehemothLabz provides research-grade SLU-PP-332 manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity.

Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research

Disclaimer

SLU-PP-332 is intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind.

Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines.

Improper handling or use outside of controlled research settings is strictly prohibited.

References

• Möller, T., Krug, O., & Thevis, M. (2026). In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid communications in mass spectrometry : RCM, 40(8), e70039. https://doi.org/10.1002/rcm.70039
• Billon, C., Schoepke, E., Avdagic, A., Chatterjee, A., Butler, A. A., Elgendy, B., Walker, J. K., & Burris, T. P. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. The Journal of pharmacology and experimental therapeutics, 388(2), 232–240. https://doi.org/10.1124/jpet.123.001733